About Sayre Therapeutics
Sayre Therapeutics is a company based in Bengaluru (India) founded in 2015 by Shukrit Sudhir Chimote.. Sayre Therapeutics has raised $7.9 million across 3 funding rounds from investors including Accel, InnoVen Capital and Aarin Capital. The company has 25 employees as of April 04, 2024. Sayre Therapeutics offers products and services including Dinutuximab Beta, Neratinib, Darinaparsin, and Carmustine Wafers.
- Headquarter Bengaluru, India
- Employees 25 as on 04 Apr, 2024
- Founders Shukrit Sudhir Chimote
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Sayre Therapeutics Private Limited
- Date of Incorporation 07 Apr, 2015
- Jurisdiction Bangaluru, Karnataka, India
-
Annual Revenue
$2.14 M (USD)22.31as on Mar 31, 2023
-
Net Profit
$-63.08 K (USD)43.78as on Mar 31, 2023
-
EBITDA
$260.02 (USD)100.15as on Mar 31, 2023
-
Total Equity Funding
$7.9 M (USD)
in 3 rounds
-
Latest Funding Round
$1 M (USD), Debt – Venture
Jun 01, 2017
-
Investors
Accel
& 2 more
-
Employee Count
25
as on Apr 04, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sayre Therapeutics
Sayre Therapeutics offers a comprehensive portfolio of products and services, including Dinutuximab Beta, Neratinib, Darinaparsin, and Carmustine Wafers. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets rare diseases in oncology for improved patient outcomes.
Oncology drug for treating specific cancers effectively.
Therapy for life-threatening diseases with targeted applications.
Delivers chemotherapy directly to tumors in oncology.
Unlock access to complete
Unlock access to complete
Funding Insights of Sayre Therapeutics
Sayre Therapeutics has successfully raised a total of $7.9M across 3 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $1 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Debt – Venture — $1.0M
-
First Round
First Round
(23 Jun 2015)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2017 | Amount | Debt – Venture - Sayre Therapeutics | Valuation |
investors |
|
| Jan, 2017 | Amount | Series A - Sayre Therapeutics | Valuation | Accel | |
| Jun, 2015 | Amount | Series A - Sayre Therapeutics | Valuation | Accel , Aarin Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Sayre Therapeutics
Sayre Therapeutics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Accel, InnoVen Capital and Aarin Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt financing is extended to companies across multiple sectors.
|
Founded Year | Domain | Location | |
|
Accel is recognized as a leading venture capital firm.
|
Founded Year | Domain | Location | |
|
Venture funding in technology-intensive businesses within healthcare, education, and India-centric markets.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Sayre Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Sayre Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Sayre Therapeutics Comparisons
Competitors of Sayre Therapeutics
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Sayre Therapeutics
Frequently Asked Questions about Sayre Therapeutics
When was Sayre Therapeutics founded?
Sayre Therapeutics was founded in 2015.
Where is Sayre Therapeutics located?
Sayre Therapeutics is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Who is the current CEO of Sayre Therapeutics?
Shukrit Sudhir Chimote is the current CEO of Sayre Therapeutics. They have also founded this company.
Is Sayre Therapeutics a funded company?
Sayre Therapeutics is a funded company, having raised a total of $7.9M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3.9M, raised on Jun 23, 2015.
How many employees does Sayre Therapeutics have?
As of Apr 04, 2024, the latest employee count at Sayre Therapeutics is 25.
What is the annual revenue of Sayre Therapeutics?
Annual revenue of Sayre Therapeutics is $2.14M as on Mar 31, 2023.
What does Sayre Therapeutics do?
Founded in 2015 and based in Bengaluru, India, Sayre Therapeutics operates in the pharmaceutical sector, focusing on rare and life-threatening diseases. Breakthrough therapies are brought to market through collaborations with global licensors. Clinical studies are tailored to diverse patient populations, and regulatory pathways are streamlined. Commercialization efforts are supported by expertise in clinical research, regulatory affairs, sales, and marketing to ensure market access for patients.
What products or services does Sayre Therapeutics offer?
Sayre Therapeutics offers Dinutuximab Beta, Neratinib, Darinaparsin, and Carmustine Wafers.
Who are Sayre Therapeutics's investors?
Sayre Therapeutics has 3 investors. Key investors include Accel, InnoVen Capital, and Aarin Capital.
What is Sayre Therapeutics's valuation?
The valuation of Sayre Therapeutics is $20.05M as of Jan 2017.